Hypertension

CCBs, ACE inhibitors, ARBs and β-blockers. Every class here is off-patent and deeply multi-sourced — the most crowded field in the register.

30.3%

Prevalence

6,300,000

Estimated patients

44%

On treatment

RM 0.3–1.7B

Market / yr*

Burden: NHMS 2019 / DOSM 2023 (2019) · * Coarse open estimate — NHMS 2019 treated patients × MOH published therapy cost (~1 DDD/day). Order-of-magnitude; precise molecule-level size & market concentration are in the read.

Market structure, at a glance.

The 9 tracked molecules in this field, grouped by makers and patent status. A neutral count — no verdict.

3 generic-open

6 multi-source

Generic-open — off-patent, generics registeredMulti-source — 10+ registered makers

Generic-open3 molecules

Perindopril

9 registered maker(s) · off-patent, generics registered · ACE inhibitor

Enalapril

9 registered maker(s) · off-patent, generics registered · ACE inhibitor

Metoprolol

8 registered maker(s) · off-patent, generics registered · β-blocker

Multi-source6 molecules

Amlodipine

41 registered makers · market already open · CCB

Telmisartan

18 registered makers · market already open · ARB

Atenolol

15 registered makers · market already open · β-blocker

Losartan

14 registered makers · market already open · ARB

Bisoprolol

12 registered makers · market already open · β-blocker

Valsartan

11 registered makers · market already open · ARB